MedTrace Logo

Preemptive Strike With Bortezomib in Multiple Myeloma Patients

NCT00657553 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-11-20

Study results available
· View outcomes & findings →

Summary

To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.

Conditions

Interventions

DRUG

Bortezomib

Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Bart Barlogie, MD, PhD · UAMS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00657553 on ClinicalTrials.gov